Common Stock Valuation Ratios (Price Multiples)

Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).

Current Valuation Ratios
Historical Valuation Ratios (Summary)
Price to Earnings (P/E)
Price to Operating Profit (P/OP)
Price to Sales (P/S)
Price to Book Value (P/BV)

Paying user area

Try for free

Celgene Corp. pages available for free this week:

The data is hidden behind: . Unhide it.

Get full access to the entire website from $10.42/mo, or
get 1-month access to Celgene Corp. for $22.49.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Current Valuation Ratios

Celgene Corp., current price multiples

	Celgene Corp.		AbbVie Inc.	Amgen Inc.	Bristol-Myers Squibb Co.	Danaher Corp.	Eli Lilly & Co.	Gilead Sciences Inc.	Johnson & Johnson	Merck & Co. Inc.	Moderna Inc.	Pfizer Inc.	Regeneron Pharmaceuticals Inc.	Thermo Fisher Scientific Inc.
Selected Financial Data
Current share price (P)
No. shares of common stock outstanding
Growth rate (g)

Earnings per share (EPS)
Next year expected EPS
Operating profit per share
Sales per share
Book value per share (BVPS)
Valuation Ratios (Price Multiples)
Price to earnings (P/E)
Price to next year expected earnings
Price-earnings-growth (PEG)
Price to operating profit (P/OP)
Price to sales (P/S)
Price to book value (P/BV)

Based on: 10-K (reporting date: 2018-12-31).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.

Historical Valuation Ratios (Summary)

Celgene Corp., historical price multiples

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	Price to earnings (P/E)
	Price to operating profit (P/OP)
	Price to sales (P/S)
	Price to book value (P/BV)

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

Download chart

Valuation ratio	Description	The company
P/E ratio	The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings.	Celgene Corp. P/E ratio decreased from 2016 to 2017 and from 2017 to 2018.
P/OP ratio	Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit.	Celgene Corp. P/OP ratio decreased from 2016 to 2017 and from 2017 to 2018.
P/S ratio	An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative.	Celgene Corp. P/S ratio decreased from 2016 to 2017 and from 2017 to 2018.
P/BV ratio	The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return.	Celgene Corp. P/BV ratio decreased from 2016 to 2017 and from 2017 to 2018.

Price to Earnings (P/E)

Celgene Corp., historical P/E calculation, comparison to benchmarks

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	No. shares of common stock outstanding¹
	Selected Financial Data (US$)
	Net income (in millions)
	Earnings per share (EPS)²
	Share price^1, 3
	Valuation Ratio
	P/E ratio⁴
	Benchmarks
	P/E Ratio, Competitors⁵
	AbbVie Inc.
	Amgen Inc.
	Bristol-Myers Squibb Co.
	Danaher Corp.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Moderna Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Thermo Fisher Scientific Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

¹ Data adjusted for splits and stock dividends.

² 2018 Calculation
EPS = Net income ÷ No. shares of common stock outstanding
= ÷ =

³ Closing price as at the filing date of Celgene Corp. Annual Report.

⁴ 2018 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =

⁵ Click competitor name to see calculations.

Download chart

Valuation ratio	Description	The company
P/E ratio	The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings.	Celgene Corp. P/E ratio decreased from 2016 to 2017 and from 2017 to 2018.

Price to Operating Profit (P/OP)

Celgene Corp., historical P/OP calculation, comparison to benchmarks

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	No. shares of common stock outstanding¹
	Selected Financial Data (US$)
	Operating income (in millions)
	Operating profit per share²
	Share price^1, 3
	Valuation Ratio
	P/OP ratio⁴
	Benchmarks
	P/OP Ratio, Competitors⁵
	AbbVie Inc.
	Amgen Inc.
	Bristol-Myers Squibb Co.
	Danaher Corp.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Moderna Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Thermo Fisher Scientific Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

¹ Data adjusted for splits and stock dividends.

² 2018 Calculation
Operating profit per share = Operating income ÷ No. shares of common stock outstanding
= ÷ =

³ Closing price as at the filing date of Celgene Corp. Annual Report.

⁴ 2018 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =

⁵ Click competitor name to see calculations.

Download chart

Valuation ratio	Description	The company
P/OP ratio	Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit.	Celgene Corp. P/OP ratio decreased from 2016 to 2017 and from 2017 to 2018.

Price to Sales (P/S)

Celgene Corp., historical P/S calculation, comparison to benchmarks

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	No. shares of common stock outstanding¹
	Selected Financial Data (US$)
	Net product sales (in millions)
	Sales per share²
	Share price^1, 3
	Valuation Ratio
	P/S ratio⁴
	Benchmarks
	P/S Ratio, Competitors⁵
	AbbVie Inc.
	Amgen Inc.
	Bristol-Myers Squibb Co.
	Danaher Corp.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Moderna Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Thermo Fisher Scientific Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

¹ Data adjusted for splits and stock dividends.

² 2018 Calculation
Sales per share = Net product sales ÷ No. shares of common stock outstanding
= ÷ =

³ Closing price as at the filing date of Celgene Corp. Annual Report.

⁴ 2018 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =

⁵ Click competitor name to see calculations.

Download chart

Valuation ratio	Description	The company
P/S ratio	An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative.	Celgene Corp. P/S ratio decreased from 2016 to 2017 and from 2017 to 2018.

Price to Book Value (P/BV)

Celgene Corp., historical P/BV calculation, comparison to benchmarks

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	No. shares of common stock outstanding¹
	Selected Financial Data (US$)
	Stockholders’ equity (in millions)
	Book value per share (BVPS)²
	Share price^1, 3
	Valuation Ratio
	P/BV ratio⁴
	Benchmarks
	P/BV Ratio, Competitors⁵
	AbbVie Inc.
	Amgen Inc.
	Bristol-Myers Squibb Co.
	Danaher Corp.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Moderna Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Thermo Fisher Scientific Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

¹ Data adjusted for splits and stock dividends.

² 2018 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =

³ Closing price as at the filing date of Celgene Corp. Annual Report.

⁴ 2018 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =

⁵ Click competitor name to see calculations.

Download chart

Valuation ratio	Description	The company
P/BV ratio	The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return.	Celgene Corp. P/BV ratio decreased from 2016 to 2017 and from 2017 to 2018.

	Celgene Corp.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality
Stock Price Trends

	All companies
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality
Stock Price Trends

Celgene Corp. (NASDAQ:CELG)

Common Stock Valuation Ratios (Price Multiples)

Paying user area

Try for free

Current Valuation Ratios

Historical Valuation Ratios (Summary)

Price to Earnings (P/E)

Price to Operating Profit (P/OP)

Price to Sales (P/S)

Price to Book Value (P/BV)